Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction

NCT00149058 is registered in ClinicalTrials.gov with Hammersmith Hospitals NHS Trust as lead sponsor.

NCT NCT00149058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00149058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction
Lead sponsor
Hammersmith Hospitals NHS Trust
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2005
Completion date
January 31, 2008
Enrollment
124
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction